• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Sanofi, Teva Ink Deal to Develop Inflammatory Bowel Disease Treatment


Collaboration to focus on ulcerative colitis and Crohn’s disease.

3d rendered medically accurate illustration of a womans large intestine. Image Credit: Adobe Stock Images/SciePro

Image Credit: Adobe Stock Images/SciePro

Sanofi and Teva Pharmaceuticals, a US subsidiary of Teva Pharmaceutical Industries Ltd., announced in a company press release plans to partner on development and commercialization of TEV’574, currently in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's disease, two types of inflammatory bowel disease. Under terms of the collaboration, Teva will receive an initial payment of $500 million with the potential to earn up to $1 billion in development and launch milestones.

“This is a new era for Teva, and our robust, innovative pipeline is key to our Pivot to Growth strategy,” said Richard Francis, president, CEO, Teva, in the aforementioned release. “This collaboration further validates the great science that Teva has to offer with our internally developed anti-TL1A. We are honored to partner with Sanofi to bring their proven capabilities, leadership, and success in the immunology and gastroenterology space together with our capabilities to optimize development and global launches.”

Reference: Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment. Sanofi. October 4, 2023. Accessed October 4, 2023. https://www.globenewswire.com/news-release/2023/10/04/2754287/0/en/Press-Release-Sanofi-and-Teva-announce-exclusive-collaboration-to-deliver-inflammatory-bowel-disease-treatment.html

Related Videos
Related Content